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SIGNIFICANCE
Skin involvement in Waldenström’s macroglobulinaemia is 
poorly described, and diagnosis of this disorder may be dif-
ficult. Many differential diagnoses are possible (other lym-
phomas, primary cutaneous lymphoma, etc.). Describing 2 
aspects of Waldenström’s macroglobulinaemia (infiltration 
by lymphoplasmacytic tumour cells or histological transfor-
mation into diffuse large B-cell lymphoma) allows the iden-
tification of clinical, histological and immunohistochemical 
diagnostic aids. Detection of the MYD88 L265P mutation is 
of interest. This study identified a characteristic clinical pic-
ture in non-transformed cases, and was able to distinguish 
between transformed and non-transformed cases by their 
severity and poor prognosis.
Cutaneous involvement in Waldenström’s macroglobu-
linaemia (WM) has been poorly characterized. To des-
cribe this involvement, a retrospective study of 19 pa-
tients with WM and cutaneous involvement of tumour 
B cells was performed. Twelve patients (group 1) had 
lymphoplasmacytic, non-transformed cutaneous proli-
feration, while in 7 cases (group 2) cutaneous involve-
ment corresponded to histological transformation. In 
group 1, skin involvement was inaugural in 6 cases. 
The lesions were infiltrated plaques (83%), papules 
(25%) and tumours (42%). Four patients had a simi-
lar clinical picture (purplish, bilateral and symmetrical 
infiltration on the face). MYD88 L265P mutation was 
detected in the skin biopsy in all 6 cases tested. The 
3-year specific survival rate was 88%. In group 2, cu-
taneous transformation occurred during the follow-
up of the WM (71%). Lesions presented as ulcerated 
tumours (86%) of the trunk (57%) and lower limbs 
(57%). The 3-year specific survival rate was 22%. 
Skin involvement in WM has distinctive characteris-
tics (e.g. clinical, histological, immunohistochemical, 
MYD88 L265P mutation).
Key words: Waldenström’s macroglobulinaemia; cutaneous 
lymphoma; diffuse large B-cell lymphoma; histological trans-
formation; extranodal involvement; MYD88 L265P mutation.
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Waldenström’s macroglobulinaemia (WM) is a rare B-cell lymphoproliferative disorder characterized 
by lymphoplasmacytic bone marrow infiltration and the 
presence of a serum monoclonal immunoglobulin (Ig)M 
paraprotein. WM accounts for 1–2% of haematological 
malignancies (1, 2). Cutaneous lesions specific to WM in-
clude cutaneous macroglobulinosis and cutaneous invol-
vement of neoplastic cells. Cutaneous macroglobulinosis 
results from cutaneous IgM deposits, leading to IgM 
storage papules (3). Cutaneous involvement of neo plastic 
cells includes dermal infiltration by lymphoplasma cytic 
tumour cells and/or histological transformation to diffuse 
large B-cell lymphoma (DLBCL) involving the skin (4). 
Cutaneous macroglobulinosis has been widely described 
(3). In contrast, only isolated case reports and small 
series of lymphomatous skin involvement associated 
with WM have been reported to date (5–7). The aim 
of this multicentre retrospective study was to describe 
clinical, biological and histological features, therapeutic 
approaches, clinical outcome and prognosis of cutaneous 
involvement in WM.
MATERIALS AND METHODS
Identification of cases and inclusion criteria
The database of the French Cutaneous Lymphoma Study Group 
(GFELC) and the participating referring clinicians were queried 
to identify cases (recruitment method 1). Furthermore, cases with 
skin involvement previously included in a series of patients with 
a WM histologically transformed to DLBCL were also selected 
(recruitment method 2) (4). All cases were analysed for the fol-
lowing inclusion criteria: (i) a diagnosis of WM confirmed by a 
haematologist, based on criteria established in the Second Inter-
national Workshop on Waldenström’s macroglobulinaemia (8); 
(ii) presence at any time of skin lesions diagnosed as cutaneous 
location of B-cell lymphoma, whatever the subtype. Exclusion 
criteria were: (i) age under 18 years; (ii) non-lymphomatous cuta-
neous lesions including cutaneous macroglobulinosis, and variable 
inflammatory, non-lymphomatous disorders after examination 
by GFELC pathologists; (iii) absence of informative clinical and 
pathological data available in medical records.
Cutaneous Involvement in Waldenström’s Macroglobulinaemia
Sarah STIEN1, Eric DUROT2, Anne DURLACH3, Marie BEYLOT-BARRY4, Henri ADAMSKI5, Helmut BELTRAMINELLI6, Gérôme 
BOHELAY7, Agnès CARLOTTI8, Olivier CARPENTIER9, Pascale CORNILLET10, Romain DUBOIS11, Nathalie FRANCK12, Bérengère 
HUSSON1, Liliane LAROCHE7, Eve MAUBEC7, Christian LE CLECH13, Laurent MACHET14, Nicolas ORTONNE15, Caroline RAM-
WOLFF16, Béatrice VERGIER17 and Florent GRANGE1
Departments of 1Oncodermatology, 2Haematology and 3Biopathology, Reims University Hospital, Reims, Departments of Dermatology, 
4Bordeaux University Hospital, Bordeaux, 5Department of Dermatology, Rennes University Hospital, Rennes, France, 6Inselspital Bern 
University Hospital, University of Bern, Switzerland, 7Avicenne Hospital, Bobigny, 9Lille University Hospital, Lille, 12Hospital of Cochin, Paris, 
13Angers University Hospital, Angers, 14Tours University Hospital, Tours and 16Saint Louis Hospital, APHP, Paris, Departments of Biopathology, 
8Hospital of Cochin, Paris, 11Lille University Hospital, Lille, 15Henri Mondor Hospital, Créteil and 17Bordeaux University Hospital, Bordeaux, 
























































S. Stien et al.2/6
www.medicaljournals.se/acta
Informed consent was obtained for each patient. Patient records 
were anonymized prior to analysis. The database was built in ac-
cordance with protocol MR004 from the Commission Nationale 
de l’Informatique et des Libertés (number 2206749, 13/09/2018), 
and followed the requirements of the French authorities.
Collected data
The following data were collected at the time of WM and cutaneous 
involvement: age; sex; Eastern Cooperative Oncology Group 
(ECOG) performance status (PS); type (papules, plaques, tumours, 
ulcerated or not), colour and anatomical location of skin lesions, 
based on medical reports and available pictures; clinical symptoms 
(pain and pruritus); presence of lymphadenopathy; presence of 
extranodal non-cutaneous involvement; complete blood counts; 
serum monoclonal IgM; serum lactate dehydrogenase (LDH) 
and B2-microglobulin levels; the presence of MYD88 L265P 
mutation, detected by skin and/or blood analysis; histological 
and immunohistochemical characteristics of cutaneous lesions, 
as described on pathology reports; prognostic score, according to 
the International Prognostic Scoring System (IPSS) for WM, and 
according to the revised International Prognostic Index (R-IPI) 
for transformed WM; and follow-up data, including treatments, 
cutaneous and haematological response, date of last follow-up 
and status at last follow-up.
Statistical analysis
Quantitative variables were expressed as median and extreme 
values and qualitative variables as numbers and percentages. 
Specific survival was defined as the time from diagnosis of cu-
taneous involvement to death related to WM, or last follow-up. 
Death from other causes was considered censoring. Survival curves 
were plotted using the Kaplan–Meier method. Two groups were 
analysed separately: patients without histological transforma-
tion (group 1); and patients with histological transformation into 
DLBCL (group 2).
RESULTS
Using the first recruitment method, 12 patients were in-
cluded in group 1, and 2 patients in group 2. The second 
recruitment method identified 5 cases of histological 
transformation WM that could be included in group 2. 
A total of 12 patients were included in group 1 and 7 in 
group 2.
Among patients in group 1, the skin lesions preceded 
the diagnosis of WM in 2 cases, by 3 and 7 years, respec-
tively. In this last patient, an initial diagnosis of marginal 
zone lymphoma (MZL) had been made, and secondarily 
corrected to WM after the haematological diagnosis. In 
6 cases, the WM preceded the occurrence of cutaneous 
lesions with a median delay of 3.5 years (1–16). In these 
cases, cutaneous progression was isolated at occurrence 
of skin lesions in 3 patients, while in 3 other cases there 
was an associated haematological progression. In 4 cases 
cutaneous, lesions were concomitant to the diagnosis of 
WM and therefore revealed the disease.
In group 2, skin involvement preceded the diagnosis of 
WM in one case, thus revealing the disease. In the other 
6 cases, cutaneous involvement followed the diagnosis 
of WM with a median delay of 4 years (0.5–10).
Patients’ characteristics at cutaneous involvement
There were 12 men and 7 women, median age 70.5 years 
(range 48–84 years). Three patients (16%) had an ECOG 
PS ≥2 and 7 patients (37%) had lymphadenopathy. Extra-
nodal, non cutaneous involvement was present in 5 cases 
(26%): 3 cases in group 1 (with rectal, ocular, and adrenal 
and bone involvement, respectively), and 2 cases in group 
2 (with adrenal and bone involvement). The median level 
of serum monoclonal IgM was 10 g/l (3.9–69 g/l) with 
kappa light chain in 13 cases and lambda light chain in 
5 cases. One patient in group 1 was in haematological 
remission, without detectable serum monoclonal IgM 
at the time of skin involvement. Eight patients (42%) 
had anaemia and 2 (10.5%) had thrombopaenia. Serum 
LDH and ß2-microglobulin levels were elevated in 6 
(31.5%) and 7 (37%) cases, respectively. The median 
ß2-microglobulin level was 4.3 mg/l (2–12.4). In group 
1, according to the IPSS, 3 patients (25%) were classified 
as low-risk, 5 (42%) as intermediate risk and 4 (33%) as 
high risk. In group 2, according to the R-IPI, 5 patients 
(72%) were classified as intermediate-risk and 2 (28%) 
as high risk. The characteristics of patients in each group 
are detailed separately in Table I, showing no significant 
difference in demographic and haematological features 
at the time of cutaneous involvement.
Clinical characteristics of cutaneous lesions
In group 1, the clinical aspect could include several types 
of skin lesions in the same patient. The most common 
aspect was purplish, pink to copper red infiltrated plaques 
(83%), papules (25%) and tumours (42%). Fifty percent 
of patients had lesions on the face, 42% had lesions on 
the lower limbs, 25% on the upper limbs and 25% on the 





Age at diagnosis of cutaneous WM, years, mean 
(range)
72 (49–82) 71 (52–84)
Sex ratio M/F, n 1 2.5
Prior MGUS history, n (%) 3 (25) 1 (14)
ECOG PS  2, n (%) 2 (17) 1 (14)
Lymphadenopathy, n (%) 4 (33) 3 (43)
Extramedullary involvement (other than skin), 
n (%)
3 (25) 2 (28)
Serum IgM level, g/l, mean (range) 14 (4–69) 7.1 (3.9–13.7)
  Kappa 8 (67) 5 (72)
  Lambda 3 (25) 2 (28)
  Absent 1 (8) 0
Anaemia, n (%) 5 (42) 3 (43)
Thrombopaenia, n (%) 1 (8) 1 (14)
β2microglobulin, mg/l IPSS score, mean (range) 4.5 (2–12.4) 2.5 (2.1–2.9)
  Low-risk 3 (25) /
  Intermediate-risk 5 (42) /
  High-risk 4 (33) /
R-IPI, n (%)
  Low-risk / 0
  Intermediate-risk / 5 (72)
  High-risk / 2 (28)
WM: Waldenström’s macroglobulinaemia; MGUS: monoclonal gammopathy of 
undetermined significance; ECOG PS: Eastern Cooperative Oncology Group 
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trunk (Table II). Lesions were symmetrical and bilateral 
in 42% of cases. Four patients had a very similar clinical 
appearance, with purplish, bilateral and symmetrical infil-
tration of the cheekbones and ears (Fig. 1). Two of these 
patients also had lesions on the lower limbs. One patient 
reported a pruritus and 2 patients of painful skin lesions, 
while the other 9 patients had no symptoms related to the 
skin involvement. Lesions were ulcerated in only one case.
In group 2, the most common aspect was tumours 
(86%), often ulcerated (43%), involving the trunk (57%), 
the upper limbs (43%) and/or the lower limbs (57%).
Histological and immunohistochemical characteristics 
of cutaneous lesions
Skin biopsies of 12 patients in group 1 showed, under 
a normal epidermis, a dermal infiltrate made of small 
lymphocytes and plasma cells (10/12), or lymphoplasmo-
cytoid cells (4/12), with a nodular (2/12), diffuse (5/12) or 
interstitial (2/12) pattern, sometimes perivascular (4/12) 
or periadnexal (2/12). The cutaneous lymphoplasmacytic 
infiltrate was positive for CD20 (12/12) and BCL2 (5/7), 
and negative for CD10 (5/5), BCL6 (5/5) and CD23 
(3/3). Reactive CD-3 and CD5-positive T cells were 
often present. The Ki67 immunostaining performed in 6 
out of 12 cases showed a proliferation index not higher 
than 40%. There was a monotypic expression of IgM in 
6 cases (6/12), with monotypic surface immunoglobulin 
kappa light chain in 5 cases according to blood immuno-
globulin light chain.
Skin biopsies of patients in group 2 showed a normal 
epidermis and a total dermal and hypodermal infiltrate 
with a nodular or diffuse (2/5), reticular (1/5) or peri-
adnexal (1/5) pattern, mainly composed of large cells, 
with mature plasma cells noted in only one case. The 
large cells were positive for CD20 (5/5), BCL2 (5/5) 
and MUM 1 (2/3), and negative for CD10 (4/5), CD23 
(4/5). The Ki67 was generally increased (mean 75%). A 
monotypic surface immunoglobulin light chain, similar 
to the isotype of the serum monoclonal component was 
found in 2 cases (1 kappa and 1 lambda).
MYD88 L265P mutation
MYD88 L265P mutation was tested on the skin biopsy 
specimens of 6 patients in group 1 and was positive in all 
cases. In these patients, this mutation was also tested in 
the blood in 4 cases and was positive. In group 2, only 2 
patients were tested for MYD88 L265P mutation: in one 
patient it was detected by skin analysis and in the other 
by blood analysis. Overall, all patients (including the 2 








   Plaques 10 (83) 3 (43)
   Papules 3 (25) 1 (14)
   Nodules or tumours 5 (42) 6 (86)
Localization
   Face 6 (50) 2 (28)
   Nose 3 (25) 0
   Ears 3 (25) 0
   Eyelid 1 (8) 0
   Forehead 1 (8) 2 (28)
   Cheek 2 (17) 0
   Upper limb 3 (25) 3 (43)
   Lower limb 5 (42) 4 (57)
   Trunk 3 (25) 4 (57)
Symmetrical/bilateral 5 (42) 1 (14)
Fig. 1. Four patients with similar clinical picture, with purplish, 
bilateral and symmetrical infiltration of the face (cheeks, nose, forehead 
and ears), corresponding to cutaneous involvement in non-transformed 
Waldenström’s macroglobulinaemia. Permission received from the patients 
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patients with initial diagnosis of MZL) tested for MYD88 
L265P mutation had a positive result.
Treatment and follow-up data
First- and second-line therapies in both groups after oc-
currence of cutaneous lesions are shown in Table III.
In group 1, 11/12 patients received a systemic therapy 
at the time of skin involvement. In 7 of these 11 cases, 
haematological criteria indicating treatment were pre-
sent, while in the other 4 cases the only reason to treat 
was the occurrence of skin lesions. First line treatments 
in this group most often consisted of a combination of 
rituximab and a single chemotherapeutic agent. One 
patient did not receive any treatment because he had no 
haematological criteria indicating treatment and did not 
report skin involvement. One responder patient achieved 
a complete cutaneous and haematological response after 
rituximab therapy, while 9 patients had a partial response 
and one patient had a progressive disease.
In group 2, all patients received treatment at the time 
of skin involvement and histological transformation. 
First line treatment generally consisted of a combination 
of rituximab and polychemotherapy. One patient received 
radiotherapy for his skin lesions. A complete response 
was obtained in 2 cases, one after rituximab-ifosfamid-
carboplatine-etoposide (RICE) and one after R-CHOP, 
followed by recurrence in one case.
In group 1, the median follow-up time was 6 years 
(0.5–21 years) after the diagnosis of WM and 4.5 years 
(0.5–20 years) after the onset of skin involvement. One 
patient died from WM. The 3- and 5 year-specific survival 
rate was 88% (Fig. 2a). In group 2, the median follow-up 
time was 5.5 years (0.25–10 years) after the diagnosis of 
WM and 1.4 years (0.25–3 years) after skin involvement. 
Five patients (71%) died from transformed WM. The 
3 year-specific survival rate was 22% (Fig. 2b).
DISCUSSION
Extramedullary localization of WM is rare (<5%) and 
can involve various organs and tissues, including the 
skin in 5% of cases (9). Histological transformation of 
WM to DLBCL is also very rare. In contrast with non-
transformed WM, transformed WM is associated with 
extranodal involvement in more than 90% of cases (9), 
including the skin in 12% (4). Overall, only a few case 
reports and a few small case series of WM involving the 
skin have been published (6, 7, 10–15).
This study has some limitations; it is a retrospective 
study conducted over a long period of time in multiple 
centres with heterogeneous practices; the method for 
identifying cases was not homogeneous, including both 
a dermatological recruitment of mainly non transformed 
cases identified by the GFELC, and a haematological 
recruitment of transformed cases, which prevented us 
from drawing epidemiological conclusions concerning 
Table III. Treatment for Waldenström’s macroglobulinaemia with 
cutaneous involvement
Group 1 Group 2 
No therapy, n (%) 1 (8) 0
Treatment, n (%) 11 (92) 7 (100)
Median number of regimens, mean (range) 1 (0–3) 2 (1–4)
First-line treatment, n (%) n = 12 n = 7
  Chlorambucil 4 (33) 0
  RCD 2 (17) 0
  CHOP +/– rituximab 0 5 (71)
  Ibrutinib 1 (8) 0
  Rituximab (mono-therapy) 1 (8) 0
  Bendamustine +/– rituximab 3 (25) 0
  GEMOX +/– rituximab 0 1 (14)
  Doxorubicin-cisplatin-cyclophosphamide 0 1 (14)
Second-line treatments, n (%) n = 5 n = 5
  Chlorambucil 1 (20) 0
  RCD 1 (20) 0
  Ibrutinib 1 (20) 0
  Rituximab (mono-therapy) 1 (20) 0
  Bendamustine +/– rituximab 1 (20) 1 (20)
  Fludarabin 1 (20) 0
  GEMOX +/– rituximab 0 1 (20)
  RICE 0 2 (40)
  RDHAC 0 1 (20)
  Radiotherapy 1 (20) 1 (20)
CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; GEMOX: 
gemcitabine, oxaliplatin; RCD: rituximab, cyclophosphamide, dexamethasone; 
RDHAC: rituximab, carboplatin, aracytine, dexamethasone; RICE: rituximab, 
ifosfamide, carboplatin, etoposide.
Fig. 2. Specific survival in patients with cutaneous involvement in (a) non-transformed Waldenström’s macroglobulinaemia (WM). (b) WM with 
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incidence and frequencies. However, to our knowledge, 
our study provides the largest series to date of WM in-
volving the skin. It made it possible to characterize and 
compare the clinical presentation of non transformed and 
transformed cases. Because of the long study period, 
long-term outcome in both groups could be reported.
Some 42% of patients developed skin lesions be-
fore the diagnosis of WM, making the dermatological 
examination the origin of the diagnosis. Despite the 
polymorphism of skin lesions, we identified a recurrent, 
homogeneous clinical aspect in a subgroup of 4 patients 
with non-transformed WM. This easily identifiable 
clinical picture consisted of non-ulcerated, erythematous-
violaceous plaques infiltrating symmetrically and bila-
terally the cheekbones, ears and forehead. This clinical 
aspect has been described previously in 2 case reports. 
In 1982, Mascaro et al. (10) first reported a patient with 
diffuse and purplish infiltration of both ears whose skin 
biopsy specimens showed a dermal infiltration by lymp-
hoplasmocytic tumour cells secondarily linked to WM. 
Similarly, in 2003, Chan et al. (14) described a woman 
with prominent violaceous dermal nodules and confluent 
plaques over the lower forehead, eyebrows, glabella, 
earlobes and upper cheeks. The skin biopsy showed a 
lymphoplasmacytic tumour cell infiltrate and the blood 
and bone marrow analyses were consistent with WM. 
Although a preferential location on the face, especially 
a symmetrical infiltration of the ears, has already been 
described in other haematological B-cell malignancies, 
such as chronic lymphocytic leukaemia (CLL) (16), ex-
tensive, symmetrical violaceous plaques including both 
the ears and the centre of the face, as observed in our 
series, seems widely suggestive of cutaneous WM and 
should be investigated accordingly.
Patients in group 2 showed a different, less specific 
clinical picture, with nodules and tumours, often rapidly 
growing and ulcerated, mainly located on the trunk 
and lower limbs. In the lower limbs, the clinical and 
pathological presentation could first be suggestive of a 
primary cutaneous diffuse large B-cell lymphoma, leg 
type (PCDLBCL-LT).
The histological characteristics of cutaneous lesions of 
WM have been poorly described and the diagnosis may 
be difficult on skin biopsies only, as confirmed in our se-
ries. The main differential diagnoses are PCDLBCL- LT 
in transformed cases and MZL in non transformed cases 
(17). In our study, skin lesions were first suggestive of 
primary cutaneous MZL in 3 cases. In one of these pa-
tients, first presenting with small skin lesions restricted to 
the eyelid and the calf, a WM was diagnosed 7 years later 
on haematological criteria. Skin biopsies were reviewed 
and further analysed, and the MYD88 L265P mutation 
was identified, leading to the diagnosis of cutaneous in-
volvement in WM. In the 2 other cases, the diagnosis of 
primary cutaneous MZL was first considered on pathology 
reports, but skin involvement in WM was finally diagnosed 
in the clinical and haematological context (bone marrow 
biopsy). MYD88 L265P mutation was positive in the skin 
in one of these 2 cases and was not investigated in the 
other. In a recent monocentre German study (18), 9 out of 
23 patients with a diagnosis of primary cutaneous MZL 
had a blood paraproteinaemia, corresponding in 4 cases 
to a monoclonal IgM, and more frequent relapse were 
observed in these patients than in the group with primary 
cutaneous MZL and no paraproteinaemia. As bone marrow 
examination was performed only in selected cases in this 
series and the MYD88 L265P mutation analysis was not 
mentioned, it remains possible that some of these patients 
had undiagnosed WM, suggesting that the frequency of 
WM with cutaneous involvement could be underestimated.
MYD88 L265P mutation has been identified as a 
specific blood molecular marker present in 91% of WM 
patients (19). Conversely, it is infrequent in IgM mono-
clonal gammopathies of uncertain significance (MGUS, 
10–50% of cases) and in MZL (7%), and is completely 
absent in multiple myeloma. (19–21). Although relati-
vely rare in systemic DLBCL (29%) (22), this muta-
tion has been detected with a high frequency (57%) in 
PCDLBCL- LT, and was shown to have an independent 
negative prognostic value in this rare subtype of primary 
cutaneous B-cell lymphoma (23). The detection of this 
mutation in skin biopsy specimens of patients with skin 
involvement in WM has been reported occasionally (7, 
24). In the current study, it was present in all cases tested 
(7/7: 6 in the group of non-transformed cases and one 
in the other group). Therefore, the presence of MYD88 
L265P mutation constitutes an important diagnostic tool 
for the distinction between primary cutaneous MZL 
and skin involvement of WM. In cutaneous large B- cell 
tumours, however, it is less distinguishing, since most 
PCLBCL- LT express the same mutation as in WM, sug-
gesting that a monoclonal IgM paraprotein should be 
tested, and an appropriate blood and systemic evaluation 
should be performed in any case of PCDLBCL- LT.
Asymptomatic patients with WM generally do not 
require a specific treatment. Criteria for systemic therapy 
include general symptoms, deleterious IgM activity, cy-
topaenia or a significant tumour mass (25). In our series, 
however, 4 patients in the group of non-transformed 
WM (one with simultaneous skin and haematological 
diagnosis and 3 with isolated cutaneous progression) 
received a systemic therapy because of their cutaneous 
lesions, although they did not meet the classic haemato-
logical criteria for treatment. In the group of transformed 
cases, the skin was the site of histological transforma-
tion to DLBCL, justifying in most cases treatment with 
rituximab and polychemotherapy (generally CHOP), as 
usually recommended (26).
Extramedullary involvement does not appear to be a 
poor prognostic factor in non-transformed cases of WM 
(9). The current study on skin involvement confirms and 
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of 88% in patients with cutaneous lesions and no histo-
logical transformation, similar to the usual survival of 
patients with WM. In contrast, histological transforma-
tion to DLBCL appears to be a milestone in the course 
of the disease (4, 27). Indeed, 71% of patients in group 
2 died of their disease, resulting in a 3-year specific 
survival rate of 22%. Whether an early diagnosis of the 
histological transformation may improve the prognosis 
remains unknown. However, dermatologists and hae-
matologists should be aware that the skin may be the 
first site of transformation, and a skin biopsy of any 
suspicious lesion should be performed in patients with 
WM, whatever the haematological status.
This study highlights 2 types of cutaneous involvement 
in WM, with quite different clinical presentation and 
prognosis. In both types, skin involvement may precede 
and reveal the haematological disease, leading to an ear-
lier diagnosis. In non-transformed cases, we identified 
a recurrent clinical picture consisting in erythematous-
violaceous plaques infiltrating the cheekbones, ears, and 
forehead symmetrically and bilaterally. In presence of 
this clinical aspect, haematological exploration for WM 
should be performed. In addition, the appearance of 
cutaneous nodules or tumours during the course of WM 
should suggest a histological transformation to DLBCL, 
associated with poor prognosis. 
In any case, the diagnosis of such lesions is based on 
close collaboration between dermatologists and hae-
matologists, allowing analysis of the clinical context, 
histology, immunohistochemistry and the detection of 
MYD88 L265P mutation.
The authors have no conflicts of interest to declare.
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